Skip to content
★ Sign in to follow
MP

Mahesh Patel V

Executive
Chairman & CEO
Lipocine Inc.
Insider activity · 24 months2 buys0 salesCumulative net flow
Total declarations
40
Company
1
▲ Purchases (26 ops.)
€447k
▼ Sales (4 ops.)
€106k

Latest filing published 06 Apr 2026 for Lipocine Inc., €44k.

Filing timeline

BuySale
Mahesh Patel V

Insider track record

Disclosed buys
26
Disclosed sells
4
Signal history

Closed purchases

Market purchases
26
Positive at T+90
69%
Median T+90
+15.0%

Based on 26 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 06 Apr 2026 · 216 days ago · €44k
    -28.0%
    Entry US$2.00 · Close 23 Oct 2026 US$1.44
  • Filed 02 Apr 2026 · 220 days ago · €44k
    -25.8%
    Entry US$1.94 · Close 23 Oct 2026 US$1.44
  • Filed 25 May 2023 · 1263 days ago · €41k
    +39.9%
    Entry US$4.74 · Close at T+365 US$6.63
  • Filed 24 Mar 2023 · 1325 days ago · €44k
    -18.4%
    Entry US$5.39 · Close at T+365 US$4.40
  • Filed 17 Mar 2023 · 1332 days ago · €16k
    -18.7%
    Entry US$5.53 · Close at T+365 US$4.49

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Mahesh Patel V: trading record in brief

Mahesh Patel V, listed as chief executive, appears in our data through filings on Lipocine Inc. shares, published by SEC (Form 4). In total, 40 filings cover trades dated from 13 November 2014 to 6 April 2026.

The open-market side counts 26 purchases for €447k alongside 4 sales for €106k. On balance, insiders were net buyers of €340k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 5 share grants and 5 option exercises. So far in 2026, the count stands at 2 purchases and no sales.

The median purchase comes to €11k. Of 18 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 26 purchases old enough to measure, the stock rose over the following 90 days in 69% of cases; the median change was +15.0%. These figures describe past trades and do not predict future prices.

The latest filing, published on 6 April 2026, reports an open-market purchase of €44k in Lipocine Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Mahesh Patel V

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations40 total
  • ▲
    Chief Executive OfficerExecutivesLipocine Inc.
    50,750 USD37SEC
    25,000 shares@ US$2.0313.7% of flowCommon stockSEC:0001493152-26-015357:0
    Canonical exit: 5 Jul 2026 (T+90)
  • ▲
    Chief Executive OfficerExecutivesLipocine Inc.
    50,500 USD23SEC
    25,000 shares@ US$2.0213.7% of flowCommon stockSEC:0001493152-26-014959:0
    Canonical exit: 1 Jul 2026 (T+90)
  • ◆
    CEO and PresidentExecutivesLipocine Inc.
    0SEC
    4,893 shares0Common StockSEC:0001493152-24-009707:0
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    43,791 USD29SEC
    8,706 shares@ US$5.0312.7% of flowCommon StockSEC:0001493152-23-019050:0
    Canonical exit: 23 Aug 2023 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    48,000 USD41SEC
    150,000 shares@ US$0.3213.8% of flowCommon StockSEC:0001493152-23-008943:0
    Canonical exit: 22 Jun 2023 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    16,500 USD28SEC
    50,000 shares@ US$0.334.9% of flowCommon StockSEC:0001493152-23-008087:0
    Canonical exit: 15 Jun 2023 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    29,250 USD29SEC
    75,000 shares@ US$0.398.8% of flowCommon StockSEC:0001493152-22-031971:0
    Canonical exit: 12 Feb 2023 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    41,000 USD27SEC
    100,000 shares@ US$0.4113.3% of flowCommon StockSEC:0001493152-22-026945:0
    Canonical exit: 26 Dec 2022 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    38,495 USD25SEC
    50,000 shares@ US$0.769911.5% of flowCommon StockSEC:0001493152-22-014014:0
    Canonical exit: 14 Aug 2022 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    27,250 USD23SEC
    25,000 shares@ US$1.097.5% of flowCommon StockSEC:0001493152-21-029268:0
    Canonical exit: 16 Feb 2022 (T+90)
  • ◇
    Chief Executive OfficerExecutivesLipocine Inc.
    0SEC
    45,000 shares0Common StockSEC:0001638599-20-000977:0
  • ▼
    Chief Executive OfficerExecutivesLipocine Inc.
    20,250 USD36SEC
    15,000 shares@ US$1.354.1% of flowCommon StockSEC:0001638599-20-000977:1
  • ◇
    Chief Executive OfficerExecutivesLipocine Inc.
    0SEC
    145,000 shares0Common StockSEC:0001638599-20-000949:0
  • ◇
    Chief Executive OfficerExecutivesLipocine Inc.
    0SEC
    122,978 shares0Common StockSEC:0001638599-20-000949:2
  • ▼
    Chief Executive OfficerExecutivesLipocine Inc.
    68,134 USD37SEC
    43,500 shares@ US$1.566313.8% of flowCommon StockSEC:0001638599-20-000949:1
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    15,340 USD28SEC
    40,000 shares@ US$0.38352.9% of flowCommon StockSEC:0001638599-20-000002:0
    Canonical exit: 30 Mar 2020 (T+90)
  • ▲
    President and CEOExecutivesLipocine Inc.
    9,975 USD28SEC
    25,000 shares@ US$0.3991.9% of flowCommon StockSEC:0001638599-19-001020:0
    Canonical exit: 9 Mar 2020 (T+90)
  • ◇
    CEO and PresidentExecutivesLipocine Inc.
    0SEC
    145,000 shares0Common StockSEC:0001638599-19-001010:0
  • ▼
    CEO and PresidentExecutivesLipocine Inc.
    17,835 USD40SEC
    43,500 shares@ US$0.413.4% of flowCommon StockSEC:0001638599-19-001010:1
  • ▲
    President and CEOExecutivesLipocine Inc.
    543 USD28SEC
    1,272 shares@ US$0.42650.1% of flowCommon StockSEC:0001638599-19-000975:0
    Canonical exit: 24 Feb 2020 (T+90)
  • ▲
    President and CEOExecutivesLipocine Inc.
    299 USD28SEC
    700 shares@ US$0.42660.1% of flowCommon StockSEC:0001638599-19-000975:1
    Canonical exit: 24 Feb 2020 (T+90)
  • ▲
    President and CEOExecutivesLipocine Inc.
    470 USD28SEC
    1,100 shares@ US$0.4270.1% of flowCommon StockSEC:0001638599-19-000975:2
    Canonical exit: 24 Feb 2020 (T+90)
  • ▲
    President and CEOExecutivesLipocine Inc.
    9,385 USD28SEC
    21,928 shares@ US$0.4281.8% of flowCommon StockSEC:0001638599-19-000975:3
    Canonical exit: 24 Feb 2020 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    1,972 USD22SEC
    4,931 shares@ US$0.39990.4% of flowCommon StockSEC:0001638599-19-000966:0
    Canonical exit: 16 Feb 2020 (T+90)
  • ▲
    CEO and PresidentExecutivesLipocine Inc.
    16,104 USD22SEC
    40,259 shares@ US$0.403.1% of flowCommon StockSEC:0001638599-19-000966:1
    Canonical exit: 16 Feb 2020 (T+90)

25 of 40 declarations